Innovent Biologics (1801) Investor Presentation summary

Market overview and unmet needs

• China has the largest obese and overweight population globally, with 500 million adults affected and less than 1% on medication for weight management.

• High prevalence of comorbidities such as fatty liver disease, pre-diabetes, and dyslipidemia among overweight and obese individuals.

• 89% of obese adults and 71% of overweight adults have at least one comorbidity, highlighting the need for effective interventions.

• Existing weight management options in China are limited, with low compliance and efficacy for lifestyle interventions and pharmacotherapy prior to GLP-1 class.

Mazdutide mechanism and advantages

• Mazdutide is a dual GLP-1R/GCGR agonist, modeled after oxyntomodulin, promoting robust weight loss and metabolic benefits.

• Mechanism includes increased energy expenditure, enhanced lipolysis, and direct liver targeting for improved metabolic outcomes.

• Offers rapid and strong weight loss, reduction in waist/hip/neck circumferences, and special liver benefits.

• Reduces key cardiometabolic risk factors including blood pressure, lipids, and glucose.

Clinical development and trial design

• GLORY-1 is the first successful Phase 3 study of a GLP-1/GCG dual agonist for weight management in Chinese adults.

• 610 participants with obesity or overweight and at least one comorbidity were randomized to mazdutide 4mg, 6mg, or placebo for 48 weeks.

• Baseline characteristics were balanced, with a mean BMI of 31.1 kg/m² and 89% having at least one weight-related comorbidity.